3 Stocks Shaking Up Health Care

In the preceding video, Fool.com analyst David Williamson discusses today's three top movers in the health-care sector. First up is Threshold Pharmaceuticals (NASDAQ: THLD  ) , down 12% as it appears likely to come in second to Celgene (NASDAQ: CELG  ) in the race to move competing pancreatic cancer drugs through phase 3 trials. Peregrine (NASDAQ: PPHM  ) is another pharma in freefall, with shares down another 17% after already having lost 80% of its value in September. Finally, on the receiving end of some good news in this space is Novavax (NASDAQ: NVAX  ) , up 8% today on no specific news, and up 35% YTD.

One recent success story in the do-or-die biotech industry is Arena Pharmaceuticals. After gaining FDA approval for its innovative obesity drug, the future is looking bright, although there are still plenty of obstacles ahead for the company. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of free updates for those who sign up. To learn more and access your report today, click here now.

 

Dave Williamson and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (2) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 01, 2012, at 9:38 PM, dave1man123 wrote:

    You guys really have no idea what is going on here. You probably don't even know where the pancreas is, do you Dave?

    TH-302 is not in competition with Abraxane and never has been. I won't even get into it but the fact that you among others are allowed to write potentially influential articles is beyond laughable. Get a real job, or if you must continue to be a "fool", do it right.

  • Report this Comment On October 01, 2012, at 10:36 PM, jakehalle wrote:

    With all due respect to the "Fool"....I've followed NVAX closely for the last 3 years and the "Fool" has consistently bashed this company as a 1 star rating and way over valued. Now you're behind it or are you just hedging and covering both sides?

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2039246, ~/Articles/ArticleHandler.aspx, 9/30/2014 4:24:37 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement